BioStock: Sprint Bioscience maintains focus on developing the portfolio

With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued focus on developing the programs in the portfolio. The company will begin presenting the latest internal program in the portfolio to potential partners and a scientific council has been appointed to support the future development. BioStock contacted the company’s CEO Erik Kinnman to get his thoughts on the first quarter.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/sprint-bioscience-maintains-focus-on-developing-the-portfolio/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se